Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.41 |
| ▸ | ALB | P02768 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.41 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.41 |
| ▸ | POLG | P54098 | 2/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5155763 | 0.88 | POLB (0.59) | POLBL3MBTL1FGFR1LMNAPDE3A | |
| SCHEMBL5413913 | 0.88 | POLB (0.59) | POLBL3MBTL1FGFR1LMNAPDE3A | |
| SCHEMBL15267601 | 0.85 | POLB (0.48) | POLBL3MBTL1LMNAPDE3ACACNA1F | |
| SCHEMBL6061303 | 0.82 | L3MBTL1 (0.52) | L3MBTL1FGFR1LMNAPDE3AP2RY2 | |
| SCHEMBL14078491 | 0.81 | POLB (0.48) | POLBL3MBTL1LMNAPDE3ACACNA1F | |
| SCHEMBL22133231 | 0.81 | POLB (0.48) | POLBL3MBTL1LMNAPDE3ACACNA1F | |
| SCHEMBL20668150 | 0.80 | DNMT1 (0.35) | ALB | |
| SCHEMBL11806529 | 0.79 | L3MBTL1 (0.58) | L3MBTL1LMNAP2RY2P2RY6THRB | |
| SCHEMBL26233311 | 0.79 | POLB (0.54) | POLBL3MBTL1POLGP2RY2P2RY4 | |
| SCHEMBL2580883 | 0.78 | POLB (0.59) | POLBLMNAPDE3ACACNA1FALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169765-B1 | Acyl deoxyribonucleoside derivatives and uses thereof | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| US-20040192635-A1 | Acyl deoxyribonucleoside derivatives and uses thereof | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-09-30 | — | — | US | disclosed |
| US-6743782-B1 | ACYL DERIVATIVE OF 2'-DEOXYADENOSINE; TREATING OR PREVENTING RADIATION, MUTAGEN AND SUNLIGHT-INDUCED CELLULAR DAMAGE, IMPROVING WOUND HEALING AND TISSUE REPAIR, AMELIORATING THE EFFECTS OF AGING; ENHANCE BIOAVAILABILITY | WELLSTAT THERAPEUTICS CORPORATION | 2004-06-01 | — | — | US | disclosed |
| EP-0712629-B1 | Acyl deoxyribonucleoside derivatives and uses thereof | WELLSTAT THERAPEUTICS CORP (US) | 2003-06-18 | — | — | EP | disclosed |
| US-6348451-B1 | WOUND HEALING AGENTS FOR ANIMALS | PRO-NEURON, INC. | 2002-02-19 | — | — | US | disclosed |
| US-6306834-B1 | METHODS OF TREATING OR PREVENTING RADIATION, MUTAGEN AND SUNLIGHT-INDUCED BIOLOGICAL DAMAGE, METHODS FOR IMPROVING WOUND HEALING AND TISSUE REPAIR, COMPRISING ADMINISTERING THE COMPOSITIONS OF THE PRESENT INVENTION TO AN ANIMAL. | PRO-NEURON, INC. | 2001-10-23 | — | — | US | disclosed |
| US-6297222-B1 | TREATING OR PREVENTING RADIATION, MUTAGEN AND SUNLIGHT-INDUCED BIOLOGICAL DAMAGE, AND METHODS FOR IMPROVING WOUND HEALING AND TISSUE REPAIR | PRO-NEURON, INC. | 2001-10-02 | — | — | US | disclosed |
| US-6103701-A | ADMINISTERING COMPOSITIONS COMPRISING ACYL DERIVATIVES OF 2'-DEOXYRIBONUCLEOSIDES; FOR IMPROVING WOUND HEALING AND TISSUE REPAIR | VON BORSTEL REID WARREN (US) | 2000-08-15 | — | — | US | disclosed |
| US-6020322-A | Acyl deoxyribonucleoside derivatives and uses thereof | PRO-NEURON, INC. (US) | 2000-02-01 | — | — | US | disclosed |
| US-6020320-A | Acyl deoxyribonucleoside derivatives and uses thereof | PRO-NEURON, INC. (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0355131-B1 | ACYL DEOXYRIBONUCLEOSIDE DERIVATIVES AND USES THEREOF | PRO NEURON INC (US) | 1996-09-04 | — | — | EP | disclosed |
| EP-0712629-A1 | Acyl deoxyribonucleoside derivatives and uses thereof | PRO-NEURON, INC. (US) | 1996-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192635-A1 | Acyl deoxyribonucleoside derivatives and uses thereof | UNG, OGG1, NQO1 | POLB 46/4885L3MBTL1 1306/4885FGFR1 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.